Drugs / nitrocamptothecin
nitrocamptothecin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00005820 | May 2000 → Sep 2004 | prostate cancer | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | nitrocamptothecin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00005820 ↗ |
| Known as | 9-NC | “9-nitrocamptothecin (9-NC) a novel, oral camptothecin analogue was tested as second line chemotherapy for patients with progressive hormone refractory prostate cancer.” PMID 15464920 ↗ Sep 2004 |
| Known as | 9-nitrocamptothecin | “9-nitrocamptothecin (9-NC) a novel, oral camptothecin analogue was tested as second line chemotherapy for patients with progressive hormone refractory prostate cancer.” PMID 15464920 ↗ Sep 2004 |
| Route | Oral | “9-NC was administered orally at the dose of 1.5 mg/m2/d for 5 days each week for 3 weeks, followed by rest for 1 week.” PMID 15464920 ↗ Sep 2004 |